Literature DB >> 11295362

Neuroprotective effect of hexasulfobutylated C60 on rats subjected to focal cerebral ischemia.

S S Huang1, S K Tsai, C L Chih, L Y Chiang, H M Hsieh, C M Teng, M C Tsai.   

Abstract

The effects of hexasulfobutylated C60 (FC4S), a free radical remover, on the total volume infarct size elicited by the damaging effects of focal cerebral ischemia were studied on Long-Evans rats in vivo. FC4S was administered intravenously either 15 min before middle cerebral artery (MCA) occlusion (pretreatment groups) or it was injected when the common carotid arteries clips were removed (treatment groups). FC4S did not alter the pH, blood gases, heart rate, or mean arterial blood pressure in either pretreatment or treatment groups of the rats. However, after administration of FC4S at dosages of 10 and 100 microg/kg, the total volume of infarction was significantly reduced in both pretreatment and treatment groups. In addition, after FC4S administration, the nitric oxide (NO) content in plasma was increased and the lactate dehydrogenase (LDH) levels was decreased. It is concluded that FC4S may be used as a neuroprotective agent on focal cerebral ischemia. The beneficial effects may be partly related to its antioxidant property and to the upregulation of NO production of the compound.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295362     DOI: 10.1016/s0891-5849(00)00505-0

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  14 in total

1.  Biomedical activities of endohedral metallofullerene optimized for nanopharmaceutics.

Authors:  Jie Meng; Dong-liang Wang; Paul C Wang; Lee Jia; Chunying Chen; Xing-Jie Liang
Journal:  J Nanosci Nanotechnol       Date:  2010-12

2.  Liposomal formulation of amphiphilic fullerene antioxidants.

Authors:  Zhiguo Zhou; Robert P Lenk; Anthony Dellinger; Stephen R Wilson; Robert Sadler; Christopher L Kepley
Journal:  Bioconjug Chem       Date:  2010-09-15       Impact factor: 4.774

3.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

Authors:  Alexandre S Basso; Dan Frenkel; Francisco J Quintana; Frederico A Costa-Pinto; Sanja Petrovic-Stojkovic; Lindsay Puckett; Alon Monsonego; Amnon Bar-Shir; Yoni Engel; Michael Gozin; Howard L Weiner
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles?

Authors:  Renée J Turner; Glen C Jickling; Frank R Sharp
Journal:  Transl Stroke Res       Date:  2011-02-12       Impact factor: 6.829

Review 5.  Central nervous system toxicity of metallic nanoparticles.

Authors:  Xiaoli Feng; Aijie Chen; Yanli Zhang; Jianfeng Wang; Longquan Shao; Limin Wei
Journal:  Int J Nanomedicine       Date:  2015-07-03

Review 6.  Nanomedicine in cerebral palsy.

Authors:  Bindu Balakrishnan; Elizabeth Nance; Michael V Johnston; Rangaramanujam Kannan; Sujatha Kannan
Journal:  Int J Nanomedicine       Date:  2013-11-01

Review 7.  Carbon Nanomaterials: Efficacy and Safety for Nanomedicine.

Authors:  Takuya Yamashita; Kohei Yamashita; Hiromi Nabeshi; Tomoaki Yoshikawa; Yasuo Yoshioka; Shin-Ichi Tsunoda; Yasuo Tsutsumi
Journal:  Materials (Basel)       Date:  2012-02-21       Impact factor: 3.623

8.  Liposome formulation of fullerene-based molecular diagnostic and therapeutic agents.

Authors:  Zhiguo Zhou
Journal:  Pharmaceutics       Date:  2013-10-18       Impact factor: 6.321

9.  Insulin renders diabetic rats resistant to acute ischemic stroke by arresting nitric oxide reaction with superoxide to form peroxynitrite.

Authors:  Li-Man Hung; Jiung-Pang Huang; Jiuan-Miaw Liao; Meng-Hsuan Yang; Dai-Er Li; Yuan-Ji Day; Shiang-Suo Huang
Journal:  J Biomed Sci       Date:  2014-09-16       Impact factor: 8.410

Review 10.  Carbon Nanomaterials Interfacing with Neurons: An In vivo Perspective.

Authors:  Michele Baldrighi; Massimo Trusel; Raffaella Tonini; Silvia Giordani
Journal:  Front Neurosci       Date:  2016-06-09       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.